目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. NEURODEGENERATIVE DISEASES DRUG MARKET, BY DISEASE TYPE (USD BILLION)
6.1. Alzheimer's Disease
6.2. Parkinson's Disease
6.3. Amyotrophic Lateral Sclerosis
6.4. Huntington's Disease
6.5. Multiple Sclerosis

7. NEURODEGENERATIVE DISEASES DRUG MARKET, BY DRUG CLASS (USD BILLION)
7.1. Disease-Modifying Therapies
7.2. Symptomatic Treatments
7.3. Neuroprotective Agents
7.4. Combination Therapies

8. NEURODEGENERATIVE DISEASES DRUG MARKET, BY ROUTE OF ADMINISTRATION (USD BILLION)
8.1. Oral
8.2. Injectable
8.3. Intravenous
8.4. Transdermal

9. NEURODEGENERATIVE DISEASES DRUG MARKET, BY PATIENT AGE GROUP (USD BILLION)
9.1. Pediatric
9.2. Adult
9.3. Geriatric

10. NEURODEGENERATIVE DISEASES DRUG MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA

11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the Neurodegenerative Diseases Drug Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Neurodegenerative Diseases Drug Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023

12. COMPANY PROFILES
12.1. Sanofi
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Johnson and Johnson
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Amgen Inc
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. Boehringer Ingelheim GmbH
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. Eli Lilly and Company
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. Biogen Inc
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. AstraZeneca PLC
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. Merck and Co Inc
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Novartis AG
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. AbbVie Inc
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Regeneron Pharmaceuticals Inc
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Roche Holding AG
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. Sun Pharmaceutical Industries Ltd
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Pfizer Inc
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
12.15. Teva Pharmaceutical Industries Ltd
12.15.1. Financial Overview
12.15.2. Products Offered
12.15.3. Key Developments
12.15.4. SWOT Analysis
12.15.5. Key Strategies

13. APPENDIX
13.1. References
13.2. Related Reports

LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 3. NORTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 4. NORTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 5. NORTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 6. NORTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 7. US NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 8. US NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 9. US NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 10. US NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 11. US NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 12. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 13. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 14. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 15. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 16. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 17. EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 18. EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 19. EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 20. EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 21. EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 22. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 23. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 24. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 25. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 26. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 27. UK NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 28. UK NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 29. UK NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 30. UK NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 31. UK NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 32. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 33. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 34. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 35. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 36. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 37. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 38. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 39. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 40. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 41. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 42. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 43. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 44. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 45. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 46. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 47. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 48. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 49. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 50. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 51. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 52. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 53. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 54. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 55. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 56. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 57. APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 58. APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 59. APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 60. APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 61. APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 62. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 63. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 64. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 65. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 66. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 67. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 68. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 69. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 70. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 71. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 72. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 73. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 74. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 75. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 76. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 77. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 78. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 79. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 80. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 81. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 82. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 83. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 84. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 85. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 86. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 87. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 88. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 89. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 90. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 91. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 92. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 93. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 94. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 95. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 96. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 97. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 98. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 99. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 100. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 101. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 102. SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 103. SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 104. SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 105. SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 106. SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 107. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 108. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 109. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 110. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 111. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 112. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 113. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 114. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 115. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 116. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 117. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 118. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 119. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 120. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 121. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 127. MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 128. MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 129. MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 130. MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 131. MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 132. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 133. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 134. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 135. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 136. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 137. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 138. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 139. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 140. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 141. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 142. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DISEASE TYPE, 2019-2032 (USD BILLIONS)
TABLE 143. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 144. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 145. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY PATIENT AGE GROUP, 2019-2032 (USD BILLIONS)
TABLE 146. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP

LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS
FIGURE 3. US NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 4. US NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 5. US NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 6. US NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 7. US NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 9. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 10. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 11. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 12. CANADA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS
FIGURE 14. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 15. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 16. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 17. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 18. GERMANY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 20. UK NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 21. UK NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 22. UK NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 23. UK NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 25. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 26. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 27. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 28. FRANCE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 30. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 31. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 32. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 33. RUSSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 35. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 36. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 37. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 38. ITALY NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 40. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 41. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 42. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 43. SPAIN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 45. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 46. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 47. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 48. REST OF EUROPE NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS
FIGURE 50. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 51. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 52. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 53. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 54. CHINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 56. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 57. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 58. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 59. INDIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 61. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 62. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 63. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 64. JAPAN NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 66. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 67. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 68. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 69. SOUTH KOREA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 71. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 72. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 73. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 74. MALAYSIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 76. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 77. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 78. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 79. THAILAND NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 81. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 82. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 83. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 84. INDONESIA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 86. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 87. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 88. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 89. REST OF APAC NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS
FIGURE 91. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 92. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 93. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 94. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 95. BRAZIL NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 97. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 98. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 99. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 100. MEXICO NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 102. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 103. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 104. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 105. ARGENTINA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 107. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 108. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 109. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 110. REST OF SOUTH AMERICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 113. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 114. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 115. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 116. GCC COUNTRIES NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 118. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 119. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 120. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 121. SOUTH AFRICA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DISEASE TYPE
FIGURE 123. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY DRUG CLASS
FIGURE 124. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 125. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY PATIENT AGE GROUP
FIGURE 126. REST OF MEA NEURODEGENERATIVE DISEASES DRUG MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF NEURODEGENERATIVE DISEASES DRUG MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF NEURODEGENERATIVE DISEASES DRUG MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: NEURODEGENERATIVE DISEASES DRUG MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: NEURODEGENERATIVE DISEASES DRUG MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: NEURODEGENERATIVE DISEASES DRUG MARKET
FIGURE 133. NEURODEGENERATIVE DISEASES DRUG MARKET, BY DISEASE TYPE, 2024 (% SHARE)
FIGURE 134. NEURODEGENERATIVE DISEASES DRUG MARKET, BY DISEASE TYPE, 2019 TO 2032 (USD Billions)
FIGURE 135. NEURODEGENERATIVE DISEASES DRUG MARKET, BY DRUG CLASS, 2024 (% SHARE)
FIGURE 136. NEURODEGENERATIVE DISEASES DRUG MARKET, BY DRUG CLASS, 2019 TO 2032 (USD Billions)
FIGURE 137. NEURODEGENERATIVE DISEASES DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
FIGURE 138. NEURODEGENERATIVE DISEASES DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2032 (USD Billions)
FIGURE 139. NEURODEGENERATIVE DISEASES DRUG MARKET, BY PATIENT AGE GROUP, 2024 (% SHARE)
FIGURE 140. NEURODEGENERATIVE DISEASES DRUG MARKET, BY PATIENT AGE GROUP, 2019 TO 2032 (USD Billions)
FIGURE 141. NEURODEGENERATIVE DISEASES DRUG MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. NEURODEGENERATIVE DISEASES DRUG MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS